Experimental Treatments: Ketamine
December 7, 2018 DOI: 10.64239/pi-vl00511 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review |
|---|---|
| Population | Treatment-resistant patients |
| Intervention | Ketamine |
| Topics | Esketamine Ketamine |
| Key findings | Ketamine's fast antidepressant effect is transient, and its mechanism may involve hydroxynorketamine acting on AMPA receptors. |
Abstract
Ketamine (an NMDA antagonist) is associated with a fast but transient antidepressant response in treatment-resistant patients Ketamine forms that are safer and able to overcome the transient effect limitation are being studied in clinical trials Ketamine’s mechanism of action could be linked to the metabolite hydroxynorketamine and its activity on glutamate AMPA receptors
Comparable studies
Other narrative reviews on ketamine, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms | 2018 | Review | |
| Mechanisms of Ketamine Action as an Antidepressant | 2018 | Review | |
| Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation Adults with treatment-resistant depression | 2021 | Review | |
| Ketamine Pharmacology: An Update (Pharmacodynamics and Molecular Aspects, Recent Findings) | 2013 | Review | |
| A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders | 2017 | Review and consensus statement |